Skip to main content
. 2019 Dec 19;17(7):677–679. doi: 10.1038/s41423-019-0348-4

Fig. 1. USP22 dominates PD-L1 deubiquitination in liver cancer to suppress antitumor immunity, while CSN5 contributes to PD-L1 stabilization in breast cancer.

Fig. 1

The expression of USP22 and CSN5 in tissue samples was analyzed individually by immunohistochemistry staining and visualized through use of the Protein Atlas program (http://proteinatlas.org). Images of stained USP22 and CSN5 from one liver cancer patient and one breast cancer patient, identified as ID 2177 and ID 2091, respectively, in the Protein Atlas program, were randomly selected and shown as indicated. IC, intracellular domain; TM, transmembrane domain; EC, extracellular domain.